SS Innovations International, Inc (SSII)

Over the past six months, SS Innovations International, Inc. completed a private placement on March 6, 2026, raising approximately $18.6 million. Regulatory approvals for its SSi Mantra system were announced in Colombia, Oman, Sri Lanka, and Kenya in March 2026, and it was approved for telesurgeries in Indonesia and the Philippines. In April 2026, the company unveiled cutting-edge surgical robotic technologies at the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India. In May 2026, the company announced that over 10,500 cumulative surgeries had been successfully performed with the SSi Mantra surgical robotic system as of April 30, 2026. Long-distance telesurgery capabilities were demonstrated at the Royal Australian College of Surgeons Annual Scientific Congress in May 2026, and the company announced the completion of robotic telesurgery for weight loss and a 4,500-mile cross-border telesurgery. In May 2026, SS Innovations filed an S-3 for a $150M shelf offering and 5.02M shares registered for resale. SSII's stock decreased by 31.9% from the beginning of 2026 to May 9, 2026, with a weekly volatility of 15%.

The provided information does not indicate any specific demand seasonality for SS Innovations International, Inc.'s products and services. The company is experiencing rapid growth and rising demand for its SSi Mantra surgical robotic system due to its differentiating features, user-friendliness, and cost-effectiveness, as well as the company's expansion into new geographies. The market for robotic surgery is generally projected to grow significantly, suggesting a continuous rather than seasonal demand trend for SS Innovations' offerings.

SS Innovations International, Inc. operates in the Healthcare sector, specifically within the Medical Devices industry, designing, manufacturing, and marketing innovative surgical robotic systems. Its flagship product, the SSi Mantra surgical robotic system, supports a wide range of multi-specialty procedures and is known for its modular arm configuration, 3D 4K vision, open-console design, and superior ergonomics. The company also offers SSi Mudra, a comprehensive suite of surgical instruments, and is developing several cutting-edge technologies, including NADI, SSi Multi-Fire Clip Applier, SSi Robotic Stapler, SSi Maya, SSi Guru, SSi XR Cognitive Skill Simulator, SSi MantraM, SSi Mantra Tele Surgeon Console (TSC), 5mm surgical instruments for pediatric and ENT surgeries, SSi Holographic Anatomy, SSi Chitrasa, SSi Mixed Reality Headset, SSi Vimana Aero Drone System, and SSi Avtara Humanoid Surgical Platform.

SS Innovations International, Inc. has its principal executive offices in Gurugram, India, and is headquartered in Fort Lauderdale, Florida, USA, with a manufacturing facility in Gurgaon, Delhi NCR, India. The SSi Mantra system has received regulatory approval in eleven countries, including India, Colombia, Oman, Sri Lanka, Kenya, Ecuador, Philippines, Guatemala, Indonesia, Ukraine, and the United Arab Emirates, with an installed base of over 200 systems as of April 30, 2026. The company is actively pursuing regulatory approvals from the US FDA and CE Mark in the European Union, with anticipated approvals in the latter part of 2025 and mid-2026, respectively, and expects to secure approvals in Australia, Vietnam, Morocco, Brunei, and Laos.

SS Innovations International, Inc. has a positive and growing brand reputation due to its focus on advanced, affordable, and accessible robotic surgery. The company consistently unveils cutting-edge surgical robotic technologies and concepts. The SSi Mantra system has been clinically validated in over 100 different types of surgical procedures in India and has surpassed 10,500 cumulative surgeries globally. The company's mission to make robotic surgery affordable and accessible to a larger global population enhances its reputation, and its rapid expansion into new international markets solidifies this. Demonstrations and successful completions of long-distance telesurgeries using the SSi Mantra system contribute positively to its image.

Individual insiders hold a significant majority of SS Innovations International, Inc., with 76% ownership. CEO Sudhir Srivastava is the largest shareholder, holding a 58% stake, followed by Frederic Moll with 11%. Manipal Global Health Services Limited holds approximately 7.7% of the company's stock. Other institutional investors include UBS Group AG, Handelsbanken Fonder AB, JNBA Financial Advisors, Inspire Investing, LLC, Eversept Partners, LP, AlphaCentric Advisors LLC, Forum Financial Management, LP, GEODE CAPITAL MANAGEMENT, LLC, AlTi Global, Inc., and Vontobel Holding Ltd. The general public holds a 16% ownership.